Minoryx Therapeutics offers pharmacological chaperones, which are small molecule drugs used for the treatment of genetic diseases.
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 30, 2020 | Debt Financing | €25M | 1 | European Investment Bank | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
European Investment Bank | Yes | Debt Financing |